EBS Emergent BioSolutions Inc

Price (delayed)

$57.14

Market cap

$3.07B

P/E Ratio

10.1

Dividend/share

N/A

EPS

$5.66

Enterprise value

$3.47B

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated ...

Highlights
The P/E is 85% lower than the 5-year quarterly average of 66.4 and 44% lower than the last 4 quarters average of 17.9
The company's revenue rose by 36% YoY
The net income has soared by 76% YoY but it has contracted by 23% from the previous quarter
EBS's EPS has soared by 73% year-on-year but it is down by 23% since the previous quarter
EBS's gross margin is down by 8% QoQ and by 3.4% YoY
Emergent BioSolutions's debt has increased by 8% YoY

Key stats

What are the main financial stats of EBS
Market
Shares outstanding
53.7M
Market cap
$3.07B
Enterprise value
$3.47B
Valuations
Price to earnings (P/E)
10.1
Price to book (P/B)
1.98
Price to sales (P/S)
1.79
EV/EBIT
8.01
EV/EBITDA
6.28
EV/Sales
2.03
Earnings
Revenue
$1.71B
EBIT
$433.6M
EBITDA
$553.2M
Free cash flow
$120.9M
Per share
EPS
$5.66
Free cash flow per share
$2.26
Book value per share
$28.81
Revenue per share
$31.88
TBVPS
$37.6
Balance sheet
Total assets
$2.92B
Total liabilities
$1.37B
Debt
$854M
Equity
$1.54B
Working capital
$784.3M
Liquidity
Debt to equity
0.55
Current ratio
3.08
Quick ratio
1.88
Net debt/EBITDA
0.73
Margins
EBITDA margin
32.4%
Gross margin
62.3%
Net margin
17.5%
Operating margin
25.1%
Efficiency
Return on assets
10.6%
Return on equity
20.8%
Return on invested capital
22.7%
Return on capital employed
17.1%
Return on sales
25.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EBS stock price

How has the Emergent BioSolutions stock price performed over time
Intraday
-0.57%
1 week
0.09%
1 month
-8.81%
1 year
-43.78%
YTD
-36.23%
QTD
-9.29%

Financial performance

How have Emergent BioSolutions's revenue and profit performed over time
Revenue
$1.71B
Gross profit
$1.06B
Operating income
$429.3M
Net income
$299.2M
Gross margin
62.3%
Net margin
17.5%
The net income has soared by 76% YoY but it has contracted by 23% from the previous quarter
EBS's operating income has soared by 63% YoY but it is down by 21% from the previous quarter
The company's revenue rose by 36% YoY
EBS's gross profit is up by 31% year-on-year but it is down by 8% since the previous quarter

Growth

What is Emergent BioSolutions's growth rate over time

Valuation

What is Emergent BioSolutions stock price valuation
P/E
10.1
P/B
1.98
P/S
1.79
EV/EBIT
8.01
EV/EBITDA
6.28
EV/Sales
2.03
The P/E is 85% lower than the 5-year quarterly average of 66.4 and 44% lower than the last 4 quarters average of 17.9
EBS's EPS has soared by 73% year-on-year but it is down by 23% since the previous quarter
The price to book (P/B) is 40% lower than the last 4 quarters average of 3.3 and 29% lower than the 5-year quarterly average of 2.8
EBS's equity is up by 29% year-on-year
The P/S is 42% below the 5-year quarterly average of 3.1 and 40% below the last 4 quarters average of 3.0
The company's revenue rose by 36% YoY

Efficiency

How efficient is Emergent BioSolutions business performance
EBS's ROIC is up by 49% YoY but it is down by 24% QoQ
The company's return on assets rose by 47% YoY but it fell by 26% QoQ
EBS's return on equity is up by 34% year-on-year but it is down by 27% since the previous quarter
EBS's ROS is up by 21% year-on-year but it is down by 20% since the previous quarter

Dividends

What is EBS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EBS.

Financial health

How did Emergent BioSolutions financials performed over time
The total assets is 113% more than the total liabilities
The total assets has grown by 18% YoY
Emergent BioSolutions's current ratio has increased by 14% YoY but it has decreased by 3.4% from the previous quarter
Emergent BioSolutions's debt is 45% lower than its equity
EBS's equity is up by 29% year-on-year
The debt to equity has decreased by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.